| 1 |
33509057 | PAX2 promoter methylation and AIB1 overexpression promote tamoxifen resistance in breast carcinoma patients. | 2022 Mar |
1 |
| 2 |
34491835 | Chelation-Tamoxifen Conjugates for Imaging of Estrogen Receptors. | 2022 Feb |
2 |
| 3 |
34821461 | Low concentrations of 17β-estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor-mediated signaling pathways. | 2022 Mar |
2 |
| 4 |
34896436 | p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes. | 2022 Jan |
1 |
| 5 |
35000145 | Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer. | 2022 Apr |
3 |
| 6 |
35023901 | Erratum: Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]. | 2022 |
1 |
| 7 |
35093383 | HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer. | 2022 Mar |
1 |
| 8 |
35121782 | NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. | 2022 Feb 4 |
1 |
| 9 |
35123662 | Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. | 2022 Mar |
2 |
| 10 |
35154350 | Paeoniflorin Enhances the Sensitivity of ER-Positive Breast Cancer Cells to Tamoxifen through Promoting Sirtuin 4. | 2022 |
4 |
| 11 |
35267559 | Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. | 2022 Feb 28 |
3 |
| 12 |
35449318 | DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer. | 2022 May |
2 |
| 13 |
35482141 | Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. | 2022 Apr 28 |
1 |
| 14 |
33112838 | Serine synthesis influences tamoxifen response in ER+ human breast carcinoma. | 2021 Jan |
4 |
| 15 |
33122307 | Hormonal Regulation of Semaphorin 7a in ER+ Breast Cancer Drives Therapeutic Resistance. | 2021 Jan 1 |
1 |
| 16 |
33262438 | Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. | 2021 Mar |
3 |
| 17 |
33398005 | MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. | 2021 Jan 4 |
1 |
| 18 |
33528846 | KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. | 2021 Apr |
1 |
| 19 |
33708885 | FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis. | 2021 Feb |
3 |
| 20 |
33755174 | Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. | 2021 Sep 11 |
2 |
| 21 |
33800852 | Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. | 2021 Mar 6 |
2 |
| 22 |
33833890 | Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer. | 2021 |
2 |
| 23 |
33860388 | ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. | 2021 Jul |
2 |
| 24 |
34057127 | Association of ERα-36 expression with the de novo resistance of tamoxifen in ER-positive breast cancer. | 2021 |
1 |
| 25 |
34069442 | Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor. | 2021 May 19 |
2 |
| 26 |
34096606 | YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant breast cancer and induce transcriptional repression of ERα. | 2021 Jun 1 |
1 |
| 27 |
34113081 | Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients. | 2021 |
1 |
| 28 |
34113127 | Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. | 2021 |
1 |
| 29 |
34149926 | HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer. | 2021 |
1 |
| 30 |
34199712 | Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. | 2021 Jun 4 |
1 |
| 31 |
34424807 | Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis. | 2021 Dec |
2 |
| 32 |
34476264 | Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer. | 2021 Sep |
2 |
| 33 |
34480554 | Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. | 2021 Dec 1 |
1 |
| 34 |
34722965 | Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes. | 2021 Oct 26 |
1 |
| 35 |
34825659 | Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+/tamoxifen treated breast cancer patients. | 2021 |
2 |
| 36 |
34899282 | Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. | 2021 |
3 |
| 37 |
31559573 | Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. | 2020 Jan |
1 |
| 38 |
32319562 | Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer. | 2020 Apr |
2 |
| 39 |
32921987 | Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer. | 2020 |
2 |
| 40 |
32929377 | The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. | 2020 |
2 |
| 41 |
33098638 | Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. | 2020 Oct 24 |
3 |
| 42 |
33099086 | Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer. | 2020 Nov |
4 |
| 43 |
33198803 | Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. | 2020 Nov 16 |
1 |
| 44 |
33357231 | Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. | 2020 Dec 23 |
2 |
| 45 |
31221824 | Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs. | 2019 Aug |
1 |
| 46 |
31670920 | EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. | 2019 |
2 |
| 47 |
31760402 | Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties. | 2019 Nov 24 |
4 |
| 48 |
29130361 | MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. | 2018 |
1 |
| 49 |
29386221 | Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. | 2018 Apr 15 |
6 |